Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Valeant Pharma, Actavis In Merger Talks : WSJ

RELATED NEWS
Trade VRX now with 

Canadian drugmaker Valeant Pharmaceuticals International, Inc. (VRX: Quote,VRX.TO: Quote) is said to be in discussions to acquire rival Actavis Inc. (ACT) for over $13 billion, according to the Wall Street Journal.

While the companies were working towards an all-stock deal announcement, few Actavis' directors were against it around the middle of this week. But the executives on both sides are still working to resurrect the deal, the journal added.

In February, Valeant announced that it was in talks to make more acquisitions, and it remains open to discuss a potential "merger of equals". Actavis currently has a market value of nearly $13 billion.

Click here to receive FREE breaking news email alerts for Valeant Pharmaceuticals International and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Micro-blogging site Twitter Inc said Tuesday after the markets closed that its second quarter loss widened from last year, hurt mainly by stock-based compensation expense, even as revenue more than doubled thanks to growth in advertising. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Pharmaceutical giant Pfizer, Inc., which was aspiring to buy British drug maker AstraZeneca Plc, reported Tuesday a profit for the second quarter that plunged 79 percent from last year, which reflected hefty gains from animal health business sales. Total revenues declined 2 percent, as it continued to be hurt by generic competition for major drugs. Home improvement and building products company Masco Corp. said Monday after the markets closed that its second quarter profit jumped 78% from last year, as revenue increased and margins improved amid strong performance of its Plumbing Products, Installation and Other Services and Decorative Architectural Products segments.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.